Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neoplasms × CX 5461 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1

Interventions

pembrolizumab 70 Paclitaxel 61 Gemcitabine 58 Carboplatin 54 Cisplatin 41 Docetaxel 39 Bevacizumab 37 Nivolumab 31 Irinotecan 28 Pemetrexed 26 Fluorouracil 26 Cyclophosphamide 26 Capecitabine 25 Erlotinib Hydrochloride 22 Cetuximab 22 venetoclax 20 Leucovorin 18 trametinib 17 Topotecan 16 Sorafenib 16 fludarabine 15 Radiotherapy 15 Oxaliplatin 15 Afatinib 15 130-nm albumin-bound paclitaxel 15 budigalimab 14 regorafenib 13 Doxorubicin 13 atezolizumab 12 Midazolam 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02719977 2023-08-04

A Phase I Study of CX5461

Canadian Cancer Trials Group

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡